Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases

Reuters

02/12

<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases

Hoth Therapeutics Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its novel exon-skipping therapy targeting allergic diseases. The allowed patent claims cover a dual-mechanism approach involving exon skipping of the FC Epsilon RI-Beta receptor and modulation of the MS4A6A gene, both key regulators in allergic and inflammatory responses. This development strengthens Hoth's intellectual property portfolio in immunology and supports future partnership and licensing opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86530) on February 12, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610921115"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610921115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610921115?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610921115","market":"nz","top_or_hot":-1,"title":"Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its novel exon-skipping therapy targeting allergic diseases. The allowed patent claims cover a dual-mechanism approach involving exon skipping of the FC Epsilon RI-Beta receptor and modulation of the MS4A6A gene, both key regulators in allergic and inflammatory responses. This development strengthens Hoth's intellectual property portfolio in immunology and supports future partnership and licensing opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86530) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-12 21:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its novel exon-skipping therapy targeting allergic diseases. The allowed patent claims cover a dual-mechanism approach involving exon skipping of the FC Epsilon RI-Beta receptor and modulation of the MS4A6A gene, both key regulators in allergic and inflammatory responses. This development strengthens Hoth's intellectual property portfolio in immunology and supports future partnership and licensing opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86530) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOTH","symbol_name":"Hoth Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL3LNDgC:1","article_id":"2610921115","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610921115","pubTimestamp":1770903196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hoth Therapeutics Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its novel exon-skipping therapy targeting allergic diseases. The allowed patent claims cover a dual-mechanism approach involving exon skipping of the FC Epsilon RI-Beta receptor and modulation of the MS4A6A gene, both key regulators in allergic and inflammatory responses. This development strengthens Hoth's intellectual property portfolio in immunology and supports future partnership and licensing opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 12, 2026, and is solely responsible","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOTH":"Hoth Therapeutics","BK4007":"制药"},"translate_title":"Hoth Therapeutics收到USPTO针对过敏性疾病的新型外显子跳跃疗法专利许可通知","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases\n    \n\n        Hoth Therapeutics Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its novel exon-skipping therapy targeting allergic diseases. The allowed patent claims cover a dual-mechanism approach involving exon skipping of the FC Epsilon RI-Beta receptor and modulation of the MS4A6A gene, both key regulators in allergic and inflammatory responses. This development strengthens Hoth's intellectual property portfolio in immunology and supports future partnership and licensing opportunities.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86530) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}